GlassScriptPhysician profile
Keith M Wille
NPI 1285658336
$9,288.82
in general payments reported to CMS, 2019-2025
18 companies · $6,438 in 2025
The $6,438 reported for 2025 was more than what 93% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $11.76 · 2021: $619 · 2022: $370 · 2023: $664 · 2024: $351 · 2025: $6,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,929 · Travel and Lodging: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,928.68 |
| Travel and Lodging | $1,523.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $5,854.39 | 2025 | Renal - Acute |
| Nxstage Medical, INC. | $570.40 | 2021-2023 | Novalung System |
| Paragonix Technologies, INC. | $394.77 | 2024-2025 | Sherpapak, Lungguard, Baroguard |
| Astrazeneca Pharmaceuticals LP | $375.00 | 2021 | |
| Astellas Pharma US INC | $357.03 | 2019-2023 | Cresemba |
| La Jolla Pharmaceutical Company | $318.72 | 2023-2025 | Giapreza, Zevtera |
| Baxter Healthcare | $291.12 | 2019-2023 | |
| Insmed, INC. | $245.16 | 2019 | |
| Fresenius USA Marketing, INC. | $223.56 | 2022-2023 | Novalung System |
| Mayne Pharma Commercial LLC | $152.64 | 2019 | |
| Allergan, INC. | $130.97 | 2019-2020 | |
| Abiomed | $129.91 | 2025 | |
| Inari Medical, INC. | $112.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Enterprises LLC | $86.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.21 | 2023 | Livtencity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.94 | 2019 | |
| Abbvie INC. | $11.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.